澳股詳情

本頁面由Tiger Trade Technology Pte. Ltd.提供服務

AROVELLA THERAPEUTICS LTD

0.070

-0.001-1.41%

成交量：25.38萬

成交額：1.77萬

市值：8,408.29萬

市盈率：-10.32

高：0.071

開：0.071

低：0.069

收：0.071

52周最高：0.125

52周最低：0.065

股本：12.01億

流通股本：8.96億

量比：0.45

換手率：0.03%

股息：- -

股息率：- -

每股收益(TTM):-0.007

每股收益(LYR):-0.007

淨資產收益率：-52.05%

總資產收益率：-32.25%

市淨率：4.44

市盈率(LYR):-10.23

資料載入中...

總覽公司新聞資訊公告

Arovella Therapeutics向美國FDA提交Ala-101首次人體一期試驗新藥研究申請

Arovella Therapeutics Ltd的CAR-iNKT細胞平台美國專利申請獲准授權

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/stock/ALA.AU/news"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"ALA.AU","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:true,,method:\"POST\",data:#items:@#symbol:\"ALA.AU\",,,,,undefined,":{"symbol":"ALA.AU","market":"AU","secType":"STK","nameCN":"AROVELLA THERAPEUTICS LTD","latestPrice":0.07,"timestamp":1774588320000,"preClose":0.071,"halted":0,"volume":253801,"delay":0,"changeRate":-0.01408450704225334,"nameEN":"AROVELLA THERAPEUTICS LTD","floatShares":895858885,"shares":1201183672,"eps":-0.006785,"marketStatus":"休市中","change":-0.001,"latestTime":"03-27 16:12:00 AEDT","open":0.071,"high":0.071,"low":0.069,"amount":17700,"amplitude":0.028169,"askPrice":0.073,"askSize":136686,"bidPrice":0.069,"bidSize":150818,"shortable":3,"etf":0,"ttmEps":-0.006785,"tradingStatus":0,"nextMarketStatus":{"tag":"開盤","tradingStatus":0,"beginTime":1774825200000},"marketStatusCode":7,"adr":0,"exchange":"ASX","adjPreClose":0.071,"openAndCloseTimeList":[[1774566000000,1774587600000]],"volumeRatio":0.44919322514880455,"lotSize":1,"tradeCurrency":"AUD","auctionPricing":{"symbol":"ALA.AU","preClose":0.071,"auctionPrice":0.07,"auctionVolume":13000,"auction":3,"marketStatus":"盘后竞价","timestamp":1774588209850}},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:true,,method:\"POST\",data:#items:@#symbol:\"ALA.AU\",,,,,undefined,":{"symbol":"ALA.AU","floatShares":895858885,"roa":"-32.25%","roe":"-52.05%","lyrEps":-0.006843,"volumeRatio":0.44919322514880455,"shares":1201183672,"dividePrice":0,"high":0.071,"amplitude":0.028169,"preClose":0.071,"low":0.069,"week52Low":0.065,"pbRate":"4.44","psRate":"26.20","week52High":0.125,"institutionHeld":0,"latestPrice":0.07,"committee":0.049154,"eps":-0.006785,"divideRate":0,"volume":253801,"delay":0,"ttmEps":-0.006785,"open":0.071,"prevYearClose":0.093,"prevWeekClose":0.071,"prevMonthClose":0.082,"prevQuarterClose":0.093,"fiveDayClose":0.071,"twentyDayClose":0.082,"sixtyDayClose":0.093},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/ALA.AU\",params:#limit:5,,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"ALA.AU\",market:\"AU\",,,undefined,":[],"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"ALA.AU\",pageSize:20,pageCount:1,lang_content:\"cn\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"1138242283","title":"Arovella Therapeutics向美國FDA提交Ala-101首次人體一期試驗新藥研究申請","url":"https://stock-news.laohu8.com/highlight/detail?id=1138242283","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1138242283?lang=zh_tw&edition=fundamental","pubTime":"2025-12-30 09:19","pubTimestamp":1767057555,"startTime":"0","endTime":"0","summary":"Arovella Therapeutics Ltd宣布已正式向美国食品药品监督管理局提交Ala-101的新药临床试验申请，该项申请旨在启动该药物的首次人体一期临床试验。这一重要进展标志着公司创新疗法开发迈入新的阶段。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7096","ALA.AU"],"gpt_icon":0},{"id":"1121490968","title":"Arovella Therapeutics Ltd的CAR-iNKT細胞平台美國專利申請獲准授權","url":"https://stock-news.laohu8.com/highlight/detail?id=1121490968","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1121490968?lang=zh_tw&edition=fundamental","pubTime":"2025-08-28 06:29","pubTimestamp":1756333754,"startTime":"0","endTime":"0","summary":"Arovella Therapeutics Ltd的CAR-iNKT细胞平台美国专利申请将获得授权批准。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7096","ALA.AU"],"gpt_icon":0}],"pageSize":20,"totalPage":1,"pageCount":1,"totalSize":2,"code":"91000000","status":"200"}]}}